Intellia Therapeutics Achieves Phase 3 Success in HAE: Gene Editing Commercialization Enters Next Phase

Hereditary Angioedema (HAE) is a rare genetic disorder that causes unpredictable, severe swelling in the face, limbs, abdomen, and larynx, significantly reducing the quality of life (QOL) for patients. For many years, treatment for this disease has relied on a symptomatic framework of symptom relief during acute attacks (on-demand treatment) and lifelong regular medication for prevention (prophylaxis). However, clinical data released in April 2026 by Intellia Therapeutics (hereinafter referred to as NTLA) suggests a fundamental shift in the treatment paradigm for this disease area. The single-dose, in vivo CRISPR gene-editing therapy 'lonvoguran ziclumeran' (lonvo-z, formerly known as NTLA-2002), which is being developed by NTLA, met its primary endpoint and all secondary endpoints in the Phase 3 HAELO study.